TITLE:
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

CONDITION:
Carcinoid Tumors

INTERVENTION:
Pasireotide (SOM230)

SUMMARY:

      Study evaluating SOM230 in patients with metastatic carcinoid tumors
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        Inclusion Criteria:

          -  Patients with biopsy-proven metastatic carcinoid tumors

          -  Patients with at least one measurable lesion (excluding bone)

          -  Patients must be considered inadequately controlled while on Sandostatin LAR therapy
             based on the symptoms of carcinoid syndrome (diarrhea and/or flushing) as defined as
             experiencing a minimum average of at least four bowel movements per day or a minimum
             average of at least two episodes of flushing per day

        Exclusion Criteria:

          -  Patients who have been previously treated with certain medications may be required to
             be without certain medications prior to entering the study

          -  Patients who have undergone major recent surgery / surgical therapy for any cause
             within 1 month

          -  Patients on any cytotoxic chemotherapy or interferon therapy within the last 2 months

          -  Patients with uncontrolled diabetes mellitus

          -  Patients who had received radiotherapy for any reason within the last 4 weeks must
             have recovered from any side effects of radiotherapy

          -  Patients who have congestive heart failure unstable angina, cardiac arrhythmia or a
             history of acute myocardial infarction within the three months preceding enrollment

          -  Patients with chronic liver disease

          -  Female patients who are pregnant or lactating, or are of childbearing potential and
             not practicing a medically acceptable method for birth control.

          -  History of immunocompromise, including a positive HIV test result

          -  Patients who have a history of alcohol or drug abuse in the 6 month period prior to
             receiving SOM230

          -  Patients who have given a blood donation (of 400 mL or more) within 2 months before
             receiving SOM230

          -  Patients who have participated in any clinical investigation with an investigational
             drug within 1 month prior to dosing

          -  Patients with additional active malignant disease within the last five years
      
